Jaguar Health, Inc. (NASDAQ: JAGX) announced that stockholders approved all five proposals at the company's annual meeting held May 22, 2026, which was adjourned until June 8, 2026.

The San Francisco-based pharmaceutical company stated the proposals were detailed in its definitive proxy statement filed with the Securities and Exchange Commission on April 30, 2026. The company did not specify the nature of the approved proposals in its announcement.

Jaguar develops prescription drugs derived from plants for gastrointestinal disease treatments. The company operates through subsidiaries including Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A., which focus on crofelemer powder development for rare gastrointestinal disorders.

The company also announced that CEO Lisa Conte will present at the Emerging Growth Conference on June 10, 2026, from 12:35 to 1:05 PM Eastern time. The presentation will be available online with an archived webcast to be made available afterward.

Jaguar's family of companies includes Magdalena Biosciences, a joint venture with Filament Health Corp. focused on developing plant-derived prescription medicines for mental health applications.